Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Gemcitabine and S-1 in Advanced Biliary Tract Cancer
NCT04172402Phase 2Completed
- Sponsor
- National Health Research Institutes
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in biliary tract cancer (BTC), sponsored by National Health Research Institutes. Started Dec 2019; status: completed.
02
Drugs
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04172402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172402.